Evidence map›Paper›PMID 40415551›Full record

ArticleJournal of medicinal chemistry2025

Peptidomimetic Phenoxymethyl Ketone Warheads as Potent Dual-Mode Inhibitors against SARS-CoV-2 M

Miriam R B Porzberg, G J Mirjam Groenewold, Heyrhyoung Lyoo, Alexander K M H Jakob, Willem H C Titulaer, Lorenzo Cavina, Katrien C K Poelaert, Marleen Zwaagstra, Cindy E J Dieteren, Jaap G H Lemmers and 11 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Miriam R B PorzbergInstitute for Molecules and Materials, Radboud University, Heyendaalseweg 135, Nijmegen 6525 AJ, The Netherlands.ORCID 0000-0002-1163-3722
G J Mirjam GroenewoldMolecular Virology Laboratory, Leiden University Center for Infectious Diseases, Leiden University Medical Center, Albinusdreef 2, Leiden 2333ZA, The Netherlands.ORCID 0000-0001-6280-7297
Heyrhyoung LyooVirology Section, Division of Infectious Diseases & Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 1, Utrecht 3584 CL, The Netherlands.ORCID 0000-0001-5806-9463
Alexander K M H JakobInstitute for Molecules and Materials, Radboud University, Heyendaalseweg 135, Nijmegen 6525 AJ, The Netherlands.
Willem H C TitulaerInstitute for Molecules and Materials, Radboud University, Heyendaalseweg 135, Nijmegen 6525 AJ, The Netherlands.
Lorenzo CavinaInstitute for Molecules and Materials, Radboud University, Heyendaalseweg 135, Nijmegen 6525 AJ, The Netherlands.
Katrien C K PoelaertVirology Section, Division of Infectious Diseases & Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 1, Utrecht 3584 CL, The Netherlands.
Marleen ZwaagstraVirology Section, Division of Infectious Diseases & Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 1, Utrecht 3584 CL, The Netherlands.
Cindy E J DieterenProtinhi Therapeutics, Transistorweg 5, Nijmegen 6534 AT, The Netherlands.
Jaap G H LemmersProtinhi Therapeutics, Transistorweg 5, Nijmegen 6534 AT, The Netherlands.
S Hakim HamdaniProtinhi Therapeutics, Transistorweg 5, Nijmegen 6534 AT, The Netherlands.ORCID 0009-0007-0949-1589
Bernd N M van BuurenProtinhi Therapeutics, Transistorweg 5, Nijmegen 6534 AT, The Netherlands.
Bart AckerschottProtinhi Therapeutics, Transistorweg 5, Nijmegen 6534 AT, The Netherlands.
Johannes PlatteeuwAvivia BV, Transistorweg 5, Nijmegen 6534 AT, The Netherlands.
Joey MichoriusAvivia BV, Transistorweg 5, Nijmegen 6534 AT, The Netherlands.
Byron E E MartinaArtemis Bioservices, Molengraaffsingel 10, Delft 2629 JD, The Netherlands.
Martin C FeitersInstitute for Molecules and Materials, Radboud University, Heyendaalseweg 135, Nijmegen 6525 AJ, The Netherlands.ORCID 0000-0003-0130-835X
Daniel GironésInstitute for Molecules and Materials, Radboud University, Heyendaalseweg 135, Nijmegen 6525 AJ, The Netherlands.
Frank J M van KuppeveldVirology Section, Division of Infectious Diseases & Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 1, Utrecht 3584 CL, The Netherlands.ORCID 0000-0001-5800-749X
Martijn J van HemertMolecular Virology Laboratory, Leiden University Center for Infectious Diseases, Leiden University Medical Center, Albinusdreef 2, Leiden 2333ZA, The Netherlands.ORCID 0000-0002-2617-9243
Floris P J T RutjesInstitute for Molecules and Materials, Radboud University, Heyendaalseweg 135, Nijmegen 6525 AJ, The Netherlands.ORCID 0000-0003-1538-3852

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Five years after the onset of the COVID-19 pandemic, there still is an unmet need for novel antivirals to battle SARS-CoV-2 and other coronaviruses. For this purpose, the development of peptidomimetics against the SARS-CoV-2 main protease (M

Indexed as

Antiviral AgentsCathepsin BCathepsin LCoronavirus 3C ProteasesCOVID-19 Drug TreatmentKetonesPeptidomimeticsProtease InhibitorsSARS-CoV-2AnimalsCOVID-19HumansVero CellsVirus ReplicationAntiviral AgentsCathepsin BCathepsin LCoronavirus 3C ProteasesCTSB protein, humanCTSL protein, humanKetonesPeptidomimeticsProtease Inhibitors

Identifiers

PMID40415551
PMCPMC12169608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.